Quotes 5-day view Delayed Nasdaq
10/15/2020
10/16/2020
10/19/2020
10/20/2020
10/21/2020
Date
42.48(c)
41.81(c)
40.27(c)
40.09(c)
38.34 Last
2 168 602
7 406 152
3 108 621
2 300 147
1 392 209 Volume
-0.72% -1.58% -3.68% -0.45% -4.37% Change
Sales 2020
1 964 M - -
Net income 2020
1 420 M - -
Net Debt 2020
3 613 M - -
P/E ratio 2020
17,2x
Yield 2020
1,53%
Sales 2021
2 145 M - -
Net income 2021
1 631 M - -
Net Debt 2021
3 950 M - -
P/E ratio 2021
14,9x
Yield 2021
1,70%
Capitalization
14 735 M 14 735 M -
EV / Sales 2020
9,34x
EV / Sales 2021
8,71x
Nbr of Employees
-
Free-Float
49,2%
Royalty Pharma plc is engaged in investing in late stage biopharmaceutical products. The Company invests in academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. The Company’s portfolio of pharmaceutical investment includes investments in approximately 45 commercial products and four development-stage product candidates.
All news about ROYALTY PHARMA PLC
News in other languages on ROYALTY PHARMA PLC
Quicken Loans parent's shares jump on debut after IPO size slashed
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends ROYALTY PHARMA PLC
Short Term Mid-Term Long Term Trends Neutral Neutral Neutral
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
OUTPERFORM
Number of Analysts
7
Average target price
51,83 $
Last Close Price
40,27 $
Spread / Highest target
39,1%
Spread / Average Target
28,7%
Spread / Lowest Target
16,7%
Please enable JavaScript in your browser's settings to use dynamic charts.
United Kingdom
Canada
France
Deutschland
Schweiz (DE)
Report
